Unicycive Therapeutics, Inc.
5150 El Camino Real, Suite A-32
Los Altos, CA 94022
June 23, 2021 |
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jeffrey Gabor
Re: | Unicycive Therapeutics, Inc. | |
Registration Statement on Form S-1 | ||
Filed May 21, 2021 | ||
File No. 333-256367 |
Ladies and Gentlemen:
Reference is made to the acceleration request letter of Unicycive Therapeutics, Inc. (the “Company”) dated June 22, 2021 (the “Acceleration Request”) requesting, pursuant to Rule 461 under the Securities Act of 1933, as amended, the Securities and Exchange Commission (the “Commission”) to accelerate the effective date of the above-referenced Registration Statement and declare the Registration Statement, as then amended, effective as of 5:00 p.m., Eastern Daylight Time, on Thursday, June 24, 2021, or as soon thereafter as practicable.
The Company hereby notifies the Commission of its withdrawal of the Acceleration Request for the above-referenced time until such time as the Company may subsequently request.
UNICYCIVE THERAPEUTICS, INC. | ||
By: | /s/ Shalabh Gupta | |
Name: | Shalabh Gupta | |
Title: | Chief Executive Officer |